Abstract |
We studied trihexyphenidyl in the treatment of torsion dystonia in a prospective, double-blind crossover protocol. Thirty-one patients completed the protocol. Twenty-two (71%) had a clinically significant response. After a mean follow-up of 2.4 years, 68% of patients continued to take trihexyphenidyl, and 42% continued to show a considerable or dramatic benefit. The 30-mg dose used was generally well tolerated. High-dosage trihexyphenidyl therapy is effective in the management of torsion dystonia.
|
Authors | R E Burke, S Fahn, C D Marsden |
Journal | Neurology
(Neurology)
Vol. 36
Issue 2
Pg. 160-4
(Feb 1986)
ISSN: 0028-3878 [Print] United States |
PMID | 3511401
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Child
- Clinical Trials as Topic
- Double-Blind Method
- Dystonia Musculorum Deformans
(drug therapy)
- Female
- Humans
- Male
- Movement
(drug effects)
- Prospective Studies
- Random Allocation
- Trihexyphenidyl
(administration & dosage, adverse effects, therapeutic use)
|